The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients?

Anna Członkowska; Adam Kobayashi; Peter Sandercock; Richard Lindley; Maria Barańska-Gierszczak; Stephanie Lewis

The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients?

Anna Członkowska, Adam Kobayashi, Peter Sandercock, Richard Lindley, Maria Barańska-Gierszczak, Stephanie Lewis

Research output: Contribution to journal › Article › peer-review

Abstract

Recombinant tissue plasminogen activator (rt-PA, alteplase) for acute ischaemic stroke was provisionally granted in Europe in 2002 and the granted license excluded many patient groups from treatment. Uncertainties about the balance of risk and benefit in several categories of patients still remain. The aim of the Third International Stroke Trial (IST-3) is to determine whether more patients can benefit from treatment. We present the rationale for the study and compare the characteristics of patients recruited to the study in Poland with those recruited in other countries.

Original language	English
Pages (from-to)	228-35
Number of pages	8
Journal	Neurologia i neurochirurgia polska
Volume	43
Issue number	3
Publication status	Published - 2009

Cite this

@article{bcdfc618f8fd48d9a8850e114736dbda,

title = "The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients?",

abstract = "Recombinant tissue plasminogen activator (rt-PA, alteplase) for acute ischaemic stroke was provisionally granted in Europe in 2002 and the granted license excluded many patient groups from treatment. Uncertainties about the balance of risk and benefit in several categories of patients still remain. The aim of the Third International Stroke Trial (IST-3) is to determine whether more patients can benefit from treatment. We present the rationale for the study and compare the characteristics of patients recruited to the study in Poland with those recruited in other countries.",

author = "Anna Cz{\l}onkowska and Adam Kobayashi and Peter Sandercock and Richard Lindley and Maria Bara{\'n}ska-Gierszczak and Stephanie Lewis",

year = "2009",

language = "English",

volume = "43",

pages = "228--35",

journal = "Neurologia i neurochirurgia polska",

issn = "0028-3843",

publisher = "Via Medica",

number = "3",

}

TY - JOUR

T1 - The Third International Stroke Trial

T2 - Thrombolysis (IST-3) in Poland: are we recruiting the right patients?

AU - Członkowska, Anna

AU - Kobayashi, Adam

AU - Sandercock, Peter

AU - Lindley, Richard

AU - Barańska-Gierszczak, Maria

AU - Lewis, Stephanie

PY - 2009

Y1 - 2009

N2 - Recombinant tissue plasminogen activator (rt-PA, alteplase) for acute ischaemic stroke was provisionally granted in Europe in 2002 and the granted license excluded many patient groups from treatment. Uncertainties about the balance of risk and benefit in several categories of patients still remain. The aim of the Third International Stroke Trial (IST-3) is to determine whether more patients can benefit from treatment. We present the rationale for the study and compare the characteristics of patients recruited to the study in Poland with those recruited in other countries.

AB - Recombinant tissue plasminogen activator (rt-PA, alteplase) for acute ischaemic stroke was provisionally granted in Europe in 2002 and the granted license excluded many patient groups from treatment. Uncertainties about the balance of risk and benefit in several categories of patients still remain. The aim of the Third International Stroke Trial (IST-3) is to determine whether more patients can benefit from treatment. We present the rationale for the study and compare the characteristics of patients recruited to the study in Poland with those recruited in other countries.

M3 - Article

C2 - 19618305

SN - 0028-3843

VL - 43

SP - 228

EP - 235

JO - Neurologia i neurochirurgia polska

JF - Neurologia i neurochirurgia polska

IS - 3

ER -

The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients?

Abstract

Fingerprint

Cite this